Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa's OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a material economic interest in…
How Ireland became dependent on big pharma - and the risks ahead
In just 50 years, Ireland has become the world's third largest exporter of pharmaceuticals, with medicines now making up about 20% of Ireland's GDP. So how did Ireland become so tied to the pharma industry — and is that reliance at risk amid…
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or 'the Company') (Nasdaq:…
Strategic Partnerships at PHARMAP 2026 - Big Pharma's Shift Toward CDMOs and CMOs
Outsourcing is no longer just about cost reduction. Pharma companies now seek strategic partnerships, agility and innovation, focusing on long-term cooperations, shared risk and early CMO involvement. Underscoring this trend, Bora Pharmaceuticals…
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan') is pleased to announce that it intends to complete an offering of a debenture of the Company (the…
Kitsa Expands Global Pharma Reach, Partners with Tech Mahindra to Bring Agentic AI Medical Writing to Pharmaceutical Companies Worldwide
Through this partnership, Tech Mahindra will enhance the go-to-market capabilities to its global pharmaceutical and biotech customer base, helping organizations modernize clinical development workflows at scale. Compressing Clinical Timelines: From…
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan'), a pharmaceutical technology company focusing on developing innovative drug delivery platform…
Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in Toronto
A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing of clinical supplies and commercial products. TORONTO, March 31, 2026 /CNW/ -- Dalton Pharma Services today announced the…
Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption
Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP). The…
Lilly and Novo Show How AI Is Rewiring Big Pharma
Eli Lilly signed a $2.75 billion partnership with Hong Kong-based AI drug discovery firm Insilico Medicine, giving it exclusive rights to develop and commercialize drugs built on Insilico's Pharma.ai platform. As reported by PYMNTS on Monday (March…
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?
Apellis Pharmaceuticals (APLS) shares soared on Tuesday after Biogen (BIIB) signed a definitive agreement to acquire the biopharmaceutical firm for about $5.6 billion in cash. Biogen's proposal values APLS shares at $41 each, representing a…
Pharmalittle: We're reading about pharma delaying launches in Europe, Lilly and Biogen deals, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and balmy breezes are greeting us. Who could ask for anything more? Actually, we could — it…
Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital
Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its 'buy' rating restated by research analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $33.00 target…
Spyglass Pharma, Inc. (NASDAQ:SGP) Given Consensus Recommendation of 'Moderate Buy' by Brokerages
Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) have been given an average recommendation of 'Moderate Buy' by the six research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the…
Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN
Hennion & Walsh Asset Management Inc. increased its holdings in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 148.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The…
Receive a Daily briefing on Pharma Industry News
Get Started